Shilpa Eyes History At It Nudges Closer To Aflibercept Opportunity In India
Shilpa Biologicals Division Also Has Adalimumab In Its Sights
Executive Summary
Amid growing moves in India for local manufacturers to make and supply biosimilars, Shilpa’s biologics division has moved a step closer to becoming the first Indian company to initiate clinical trials for a biosimilar to Regeneron’s Eylea treatment for ophthalmic diseases.
You may also be interested in...
Pressure Mounts On Zydus Cadila In Q3 As Vaccine Launch Looms
Zydus Cadila found itself under pressure during Q3 following a lack of demand for COVID-19 therapeutics in India and reduced mesalamine sales in the US – but, heading into H2, exports of its novel COVID-19 vaccine ZyCov-D, as well as a number of biosimilar launches, could see its luck begin to turn.
Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk
Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.
Dr Reddy’s Pilots Sputnik V Soft Launch In India, Explores CAR-T Space
Dr Reddy’s initiates pilot roll-out of imported Russian vaccine Sputnik V, currently priced at about $13.50 per dose in India, and indicates that it hopes to bring the single-dose version Sputnik Light to the country. The Indian company also strikes a deal with a Chinese firm for a CAR-T cell therapy, an area where it hopes to “pick up skills”.